Research programme: immunomodulators - Batu Biologics

Drug Profile

Research programme: immunomodulators - Batu Biologics

Alternative Names: Cancer vaccine - Batu Biologics; hp91; Immittam™; ImmStem™; ImmXcyte™; Stem cell therapy - Batu Biologics; ValloVax™

Latest Information Update: 07 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Batu Biologics
  • Class Cancer vaccines; Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cell replacements; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Septic shock

Most Recent Events

  • 03 Mar 2017 Additional pharmacodynamics data from a preclinical study in Cancer released by Batu Biologics
  • 21 Dec 2016 ValloVax is still in Preclinical studies for Cancer in USA
  • 15 Jun 2015 Batu Biologics files for patent protection for Vallovax™ in combination with checkpoint inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top